Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Rating) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 209,800 shares, a decline of 17.4% from the June 30th total of 254,100 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average trading volume of 53,700 shares, the days-to-cover ratio is currently 3.9 days.
Hedge Funds Weigh In On Vivos Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new stake in shares of Vivos Therapeutics in the 1st quarter valued at approximately $29,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Vivos Therapeutics by 60.0% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock valued at $43,000 after acquiring an additional 7,200 shares during the period. State Street Corp raised its stake in shares of Vivos Therapeutics by 150.4% in the 1st quarter. State Street Corp now owns 45,650 shares of the company’s stock valued at $122,000 after acquiring an additional 27,417 shares during the period. National Asset Management Inc. raised its stake in shares of Vivos Therapeutics by 55.5% in the 4th quarter. National Asset Management Inc. now owns 79,270 shares of the company’s stock valued at $179,000 after acquiring an additional 28,283 shares during the period. Finally, Griffin Asset Management Inc. raised its stake in shares of Vivos Therapeutics by 63.3% in the 1st quarter. Griffin Asset Management Inc. now owns 70,200 shares of the company’s stock valued at $188,000 after acquiring an additional 27,200 shares during the period. 9.81% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Craig Hallum lowered their price target on shares of Vivos Therapeutics to $5.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th.
Vivos Therapeutics Price Performance
Vivos Therapeutics (NASDAQ:VVOS – Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.03. The firm had revenue of $3.46 million during the quarter, compared to analyst estimates of $4.50 million. As a group, equities analysts anticipate that Vivos Therapeutics will post -1 earnings per share for the current fiscal year.
Vivos Therapeutics Company Profile
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
- Get a free copy of the StockNews.com research report on Vivos Therapeutics (VVOS)
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
- Will Economics Push AUD to the Top of the Currency World?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.